Aldagen, Inc. has received CEO Cancer Gold Standard™ accreditation, recognizing the company’s commitment to taking concrete actions to reduce the cancer risk of its employees and their families through screenings, early detection, and healthy changes in lifestyle and in the workplace.
“do something bold and venturesome about cancer within your own corporate families.”
William C. Weldon, chairman and chief executive officer of Johnson & Johnson, chairs the CEO Roundtable on Cancer, a nonprofit organization of cancer-fighting CEOs who created the CEO Cancer Gold Standard™, in collaboration with the National Cancer Institute, many of its designated cancer centers, and leading health non-profit organizations and professionals.
“We are proud of the leadership that Aldagen’s CEO, Tom Amick, has demonstrated in his commitment to achieving CEO Cancer Gold Standard certification,” said Weldon. “Our Gold Standard recognizes that Aldagen’s work in developing novel biopharmaceuticals to improve health begins with a commitment to provide world-class health and wellness benefits for its employees and their family members.”
The CEO Cancer Gold Standard™ calls for companies to evaluate their health benefits and corporate culture and take extensive, concrete actions in five key areas of health and wellness to fight cancer in the workplace. To earn Gold Standard accreditation, a company must establish programs to reduce cancer risk by discouraging tobacco use; encouraging physical activity; promoting healthy diet and nutrition; detecting cancer at its earliest stages; and providing access to quality care, including participation in clinical trials. Aldagen is the 44th organization to become Gold Standard accredited. Currently, more than one million lives are covered through Gold Standard employers.